Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like ...
The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...
Bloomberg on MSN9d
Alzheimer’s drugs eyed as next big obesity-like opportunityInvestors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
The U.S. Food and Drug Administration (FDA ... Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback